Biotech Design

  • Johannes Geisler

LIFETAQ WINS ACR START-UP AWARD 2025
LIFETAQ WINS ACR START-UP AWARD 2025 2048 1366 Johannes Geisler

We, Lifetaq and Johannes Geisler Design, are honored to announce that LifeTaq-Analytics GmbH has been awarded the ACR Start-up Prize 2025, recognizing our innovation in automated 3D tissue model production developed in close collaboration with the Austrian Research Institute for Chemistry and Technology (OFI).

In a closely coordinated project, LifeTaq developed a fully automated, robot-based machine designed by Johannes Geisler Design for the cultivation of 3D tissue models. OFI then performed the critical external validation of these tissues, using them as in vitro lung models for toxicological testing. This is another great step towards animal-free testing in preclinical studies. The project lays the foundation for more efficient, economical, and ethical drug development.

We’re truly honored to receive the prestigious ACR Start-up Award and deeply grateful for the positive response from early adopters, the media, and policymakers. This recognition motivates us to keep pushing forward with our innovative approach and to create lasting impact for science and industry

– Manfred Taschner, CEO & Founder of LifeTaq-Analytics GmbH

Why this matters

Around 90% of drug candidates fail in clinical trials because animal models often cannot accurately predict human responses, a gap that costs the pharmaceutical industry billions and slows down access to life-saving therapies.

LifeTaq’s technology addresses this problem at its core. By enabling pharmaceutical companies and research partners to test compounds directly on standardized human tissue models, our system delivers more predictive, reproducible, and human-relevant data earlier in the development process. This means better decision-making, faster timelines, and a measurable reduction in animal testing, ultimately improving both research efficiency and ethical standards across the industry

Johannes Geisler and CEO Manfred Taschner on the machine “Tissura”

What`s next

Building on this milestone, LifeTaq is now preparing for pilot testing with strategic partners and the upcoming launch of its automated platform, Tissura. These next steps mark the beginning of a new chapter: enabling scalable, standardized testing solutions that can accelerate the development of safer and more effective therapies.

  • Johannes Geisler

LIFETAQ GOES ROCKETS
LIFETAQ GOES ROCKETS 1687 1687 Johannes Geisler

Want to develop drugs faster and without animal suffering? LifeTaq offers the solution for industrial production of human tissue models for the rapid and more cost-effective development of vital drugs – entirely without animal testing.

INVEST NOW ON ROCKETS!

LifeTaq marks a true turning point in drug research: The Austrian technology and biotechnology company has developed a technology that allows for the fully automated production of human tissue models.

Pharmaceutical and biotech companies can use this technology to develop important drugs significantly faster, more cost-effectively, and in the future, without animal testing, as standardized human models provide more reliable data and thus significantly shorten development cycles.

Johannes developed a design that conveys the machine’s advantages through a clean, modern appearance.

The benefits are clearly measurable: Up to 40% lower costs through automation compared to manual tissue model production, savings of up to €250,000 per machine annually, and a production capacity of over 10,000 tissues per year are already possible. LifeTaq is profitable with just four machines sold.

Johannes Geisler supports the startup Lifetaq with his industrial design expertise for the Tissura, which features a modern, modular, futuristic design language. The product is characterized by its modularity, which Geisler Design deliberately emphasized both in terms of design and appearance.

Vertical LED dividers emphasize the modular structure, creating a futuristic appearance. This modularity allows for flexible, unlimited cell cultivation, module upgrades, or reordering, allowing customers to cultivate customized cells and test medications under perfectly hygienic conditions. The housing for the pilot machine and pre series was built together with the team of  Lifetaq from Vienna.

Design Challenge

The design challenge was to transform a technically functioning machine into a design that appeared hygienic, clean, and modern, and that reflected the revolutionary technology.

Furthermore, the handling and user experience were limited by the purely technical and scientific approach. Furthermore, the modules were of different sizes, and the refrigerator was located outside the machine. The design had to be designed in such a way that technical updates could be implemented and added later.

Create Impact + Design Legacy

Design has the power to create global impact.

A technologically groundbreaking product is brought to market with the support of the modern, futuristic, and positive design created by Johannes Geisler. Laboratories, hospitals, and pharmaceutical companies can easily integrate it into everyday life. Drugs can be tested faster and more easily thanks to the modularly designed system and automated cell cultivation.

Back to top
GDPR Cookie Consent with Real Cookie Banner